Given that obesity is a common comorbidity of inflammatory bowel disease (85), further research is needed to understand the significance of the GLP-1R downregulation during inflammatory bowel disease and how GLP-1 medicines interact with inflammatory bowel disease through both metabolic improvements and direct antiinflammatory actions on the intestine. This evidence concerns the gene GLP1R and obesity disorder.